U.S. Stock Market Midday Update

Klotho Neurosciences rose 8.94%. Based on recent important news:

1. On June 10, Klotho Neurosciences announced that its licensed therapy showed potential in reducing age-related degeneration, causing the stock price to soar by 500%.

2. On June 9, the active market in the innovative drug sector boosted sentiment in pharmaceutical stocks, with some individual stocks rising more than innovative drug companies.

3. On June 4, Innovent Biologics released innovative pipeline data at the ASCO annual meeting, leading to a rise in stock price and boosting sentiment in related sectors.

Stocks with High Trading Volume in the Industry

Calidi Biotherapeutics rose 228.66%. According to recent key news:

1. On July 8, Calidi Biotherapeutics published an editorial on NetworkNewsWire, increasing market attention and significantly driving up the stock price.

2. On July 8, MTR Corporation signed an agreement for the Northern Link project with the government, which, although not directly related to Calidi, indicates market interest in infrastructure projects.

3. On July 9, Daikin Heavy Industries released a profit forecast; despite a drop in its stock price, its profit growth shows the market's emphasis on high-value delivery.

Abbvie fell 0.42%, with increased trading volume. Based on recent important news:

1. On July 9, analysts indicated that Abbvie was not on the recommended buy list, despite its rating being moderate buy, leading to a lack of market confidence and a 0.42% drop in stock price.

2. On July 9, the innovative drug industry experienced high volatility, causing investors to hold a cautious attitude towards the industry's prospects, affecting Abbvie's stock price.

3. On July 8, the application prospects of CAR-T cell therapy in autoimmune diseases attracted market attention, impacting the stock prices of related companies.

Stocks with High Market Capitalization in the Industry

Abbvie fell 0.42%, with increased trading volume. Based on recent important news:

1. On July 9, analysts indicated that Abbvie was not on the recommended buy list, despite its rating being moderate buy, leading to a lack of market confidence and a 0.42% drop in stock price.

2. On July 9, the innovative drug industry experienced high volatility, with investor biases affecting market sentiment, leading to stock price fluctuations.

3. On July 9, the application prospects of CAR-T cell therapy in autoimmune diseases attracted market attention, but failed to boost Abbvie's stock price